Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT03948841 | Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences(NETMRI) | completed | — | 41 | CHU de ReimsOTHER | 1 | May 14, 2019 |
| clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01590199 | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(MACS2002) | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02457273 | Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | completed | Phase 2 | 23 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01069653 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00605566 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00453895 | Sunitinib in Refractory Adrenocortical Carcinoma(SIRAC) | completed | Phase 2 | 39 | University of WuerzburgOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT00688623 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe(RAMSETE/CDE16) | completed | Phase 2 | 73 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01840449 | Somatuline Predictive Factors in Acromegaly and NET(SOPRANo) | completed | — | 156 | IpsenINDUSTRY | 3 | Jan 14, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00747786 | Non Interventional Post Marketing Programme in Neuroendocrine Tumours | completed | — | 40 | IpsenINDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT03017690 | Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | completed | — | 22 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03220087 | Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain(RECOSY) | completed | — | 142 | IpsenINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03085849 | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | completed | Phase 1 | 2 | Catherine ShuOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT02267967 | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | completed | Phase 1 | 81 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 13, 2018 | clinicaltrials |
| NCT00037869 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | completed | Phase 3 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT03723499 | Endoscopic Treatment of Bronchial Carcinoid Tumors | completed | — | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00926640 | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02913443 | A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Oct 19, 2018 | clinicaltrials |
| NCT01469572 | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01435122 | A Study of Axitinib in Advanced Carcinoid Tumors | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02874664 | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | completed | Phase 1 | 46 | StemcentrxINDUSTRY | 2 | Sep 24, 2018 | clinicaltrials |
| NCT01560260 | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2018 | clinicaltrials |
| NCT01413503 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01881906 | Exercise in Advanced Stage Lung Cancer Patients(EXHALE) | completed | N/A | 219 | Rigshospitalet, DenmarkOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01504399 | Rhinological Outcomes in Endonasal Pituitary Surgery | completed | — | 235 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT03623516 | Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014(OTCancer) | completed | — | 2,008 | CHU de ReimsOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT02932384 | Reducing HIV Risk With High Risk HIV Negative Black MSM-Passport to Wellness(PtW) | completed | N/A | 105 | Charles Drew University of Medicine and ScienceOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01457469 | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer | completed | Phase 1 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00298896 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | completed | Phase 2 | 55 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 26, 2018 | clinicaltrials |
| NCT00098956 | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT03592940 | The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.(NetNutr) | completed | — | 100 | Federico II UniversityOTHER | 1 | Jul 19, 2018 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2019source: clinicaltrials